Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled PC945 in Adult CF Patients With Aspergillus Infection
NCT03870841Phase 2Terminated
- Sponsor
- Pulmocide
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of opelconazole in pulmonary aspergillosis, sponsored by Pulmocide. Started Apr 2019; status: terminated.
02
Drugs
opelconazole
03
Conditions
pulmonary aspergillosis
Beyond the preview
Go deeper on NCT03870841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870841.